0

Type 2 Diabetes Market by Drug Class, Distribution Channel, and Geography - Forecast and Analysis 2023-2027

  • Published: Nov 2022
  • Pages: 173
  • SKU: IRTNTR70605
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

"The type 2 diabetes market report is a comprehensive research document that provides in-depth qualitative and quantitative intelligence. Technavio’s analysts estimate the market share growth of USD 39.37 billion from 2022 to 2027, at a CAGR of 10.94%".

Technavio has extensively analyzed 20 major vendors including Amgen Inc., AstraZeneca Plc, Baxter International Inc., Biocon Ltd., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Daiichi Sankyo Co. Ltd., DM Pharma Marketing Pvt. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Johnson & Johnson, Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Practo Technologies Pvt. Ltd., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Tonghua Dongbao Pharmaceutical Co. Ltd..

This report presents historical data on the market size and geographical analysis from 2017 to 2021. In 2017, the market size was USD 39.45 billion. From a  regional perspective, North America was the largest market in 2017 with a market value of USD 15.30 billion.

Technavio has forecasted the market from 2023 to 2027, focusing on the primary factors contributing to the growth. The market is estimated to witness a year-over-year growth of 9.49% during the forecast period. Our analysts predict that North America will be the most optimistic region that will experience significant growth during the forecast period.   

 What will the Size of the Type 2 Diabetes Market be During the Forecast Period?

Type 2 Diabetes Market Size

Download Report Sample to Unlock Statistics About the Type 2 Diabetes Market During the Forecast Period

Type 2 Diabetes Market: Key Drivers, Trends, Challenges, and Customer Landscape

The rising prevalence of diabetes is notably driving the type 2 diabetes market growth, although factors such as the low diagnosis rate may impede the market growth. Our researchers studied the data for years, with 2022 as the base year and 2023 as the estimated year, and presented the key drivers, trends, and challenges for the market. Although there has been a decrease in demand for the market during the COVID-19 pandemic, a holistic analysis of drivers will help companies refine marketing strategies to gain a competitive advantage.   

Key Type 2 Diabetes Market Driver

The rising prevalence of diabetes is notably driving the type 2 diabetes market growth. Type 2 diabetes is caused by the body's ineffective use of the insulin produced. It is the most common type of diabetes across the world. Excess body weight and a physically inactive lifestyle are the most common causes of type 2 diabetes. Type 2 diabetes is caused by hyperglycemia and metabolic alterations due to abnormalities in insulin secretion or insulin action. Until the early 2000s, the disease was common only among adults. However, the prevalence of type 2 diabetes among children has also increased. The early diagnosis of type 2 diabetes is often a challenge due to the generic symptoms that manifest at the beginning stages of the disease. Hence, once the disease is diagnosed, it is essential to provide advanced medications. Different anti-hyperglycemic drugs are used by themselves or in combination with other drugs, such as insulin, to treat type 2 diabetes. The initial steps in the treatment include weight loss plans, lifestyle changes, and the administration of metformin. The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend a patient-specific treatment approach to enhance glycemic control to treat type 2 diabetes. This is to prevent weight gain and hypoglycemia. Hence, the increasing number of people with type 2 diabetes will drive the growth of the market during the forecast period.

Key Type 2 Diabetes Market Trend

Innovations in therapies is the primary trend driving the type 2 diabetes market growth. Several vendors are introducing advanced therapeutics to treat diabetes. Incretins are GLP-1 and glucose-dependent insulinotropic polypeptides (GIPs), which are secreted by the GI tract in response to food intake. Both GLP-1 and GIPs stimulate the beta cells in the pancreas, which account for 60% of the insulin secreted after a meal. Type 2 diabetes reduces the secretion of GLP-1 and reduces the responsiveness to GIP. The benefits of incretin hormones on glycemic control include enhanced satiety, decreased GI motility, increased glucose-dependent insulin secretion, reduced glucagon secretion, and decreased hepatic glucose release. Two incretin-based drug classes are used to treat people with type 2 diabetes, including oral DPP4 inhibitors and GLP-1 receptor agonists. The pathophysiology of type 2 diabetes involves at least seven major organs and tissues, including the brain, liver, pancreas, intestines, kidneys, fat, and muscles. No single medication can impact all seven organs and tissues, which is why most people require more than one medication to treat the disease. Hence, drugs with a unique and complementary mechanism of action (MoA) are required. Therapeutics such as DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, colesevelam, and bromocriptine QR provide therapeutic options with a novel MoA. They also prevent weight gain and reduce the risk of hypoglycemia. Though all these medications are not appropriate for everyone, they offer healthcare providers several options to personalize treatments and optimize healthcare for patients.

Key Type 2 Diabetes Market Challenge

The low diagnosis rate may impede the type 2 diabetes market growth. The clinical diagnosis of type 2 diabetes might be delayed up to 12 years after its onset owing to the asymptomatic nature of the disease during its initial phases. According to the rule of halves by Wilber and Barrow, only half of the population with the disease is actually diagnosed with diabetes. Of these people, only half undergo treatment from healthcare professionals. Thus, the number of people receiving treatment and achieving the desired outcomes constitutes only a small proportion of the total population with diabetes. According to the CDC, in 2018, 34.2 million people in the US or 10.5% of the US population, had diabetes. Of these 34.2 million adults with diabetes, 26.8 million were diagnosed with diabetes, while 7.3 million people were still undiagnosed. Also, the proportion of undiagnosed diabetes was 30%-40% in Europe in 2019. In addition, as per the report of the International Diabetes Federation (IDF) Africa Region, the continent has the highest proportion of people with undiagnosed diabetes, with 60% of adults living with diabetes unaware of their condition in 2019. In Southeast Asia and Western Pacific, 52.1% of the population with diabetes remains undiagnosed. It has also been estimated that 81.1% of the undiagnosed population is from low- and middle-income countries. Thus, the low diagnosis rate prevents people from getting the necessary treatment, thus posing a challenge for the market.

Key Type 2 Diabetes Market Customer Landscape

Our analysis of the Life Cycle of the market indicates a movement from the innovator’s stage to the laggard’s stage. The report illustrates the lifecycle of the market, focusing on the adoption rates of the major countries including the US, Germany, the UK, China, and India. Technavio has included key purchase criteria, adoption rates, adoption lifecycles, and drivers of price sensitivity to help companies evaluate and develop growth strategies from 2022 to 2027.

Type 2 Diabetes Market Share by Geography

Global Type 2 Diabetes Market Customer Landscape

Parent Market Analysis

Technavio categorizes the global type 2 diabetes market as a part of the global pharmaceuticals market within the overall healthcare industry.

The parent global pharmaceuticals market covers products and companies engaged in research and development (R&D) or production of generic drugs, non-generic drugs, and veterinary drugs. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.

Who are the Major Type 2 Diabetes Market Vendors?                                     

The market is extremely competitive with businesses of all sizes, including large, medium, and small-sized companies vying to monopolize the market. The tremendous development in various fields such as product innovations and new product launches by manufacturers will drive the growth further.

Sanofi SA - The company's key offerings for type 2 diabetes patients in India, offered under its pharmaceuticals segment, include two drugs, namely Lyxumia and Zemiglo. This segment also comprises the commercial operations of the following global franchises: Specialty Care, Diabetes and Cardiovascular, and Established Prescription Products and Generics.

We also have detailed analyses of the market’s competitive landscape and offer information on 20 market vendors, including :

  • Amgen Inc.
  • AstraZeneca Plc
  • Baxter International Inc.
  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Ltd.
  • Daiichi Sankyo Co. Ltd.
  • DM Pharma Marketing Pvt. Ltd.
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc.
  • Practo Technologies Pvt. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Tonghua Dongbao Pharmaceutical Co. Ltd.

An internal and external analysis of vendors has been conducted to help companies understand the wider business environment as well as the strengths and weaknesses of key market players. If a vendor is focused only on the Type 2 diabetes market, then it is classified as a pure-play vendor.

On the other hand, a vendor with interests in multiple industries is classified as a diversified vendor. The external analysis is a qualitative assessment of the ability of a vendor to impact the market through its actions. Dominant vendors can impact the market significantly, while a weak vendor has no ability to influence the market dynamics.

What are the Revenue-generating Drug Class Segments in the Type 2 Diabetes Market?

Technavio has segmented the market based on distribution channel, drug class, and region. The market share growth by the insulin segment will be significant during the forecast period. The insulin segment of the market is expected to grow rapidly during the forecast period, as regular insulin treatment is the only cure for type 1 diabetes. In type 2 diabetes, insulin is administered when options such as diet, exercise, and oral anti-diabetic drugs fail to maintain optimal blood glucose levels. Factors such as an increase in the population with type 2 diabetes and disease awareness contribute to the growth of the global insulin market. In addition, the rising obese and older population is expected to propel the market growth.

Type 2 Diabetes Market Size 

Get full insights on the market contribution of various segments Request a PDF Sample

The insulin segment showed a gradual increase in market share with USD 13.15 billion in 2017 and continued to grow by 2021. Insulin is a peptide hormone produced by the beta cells of the islets of Langerhans (pancreatic cells). It is produced as preproinsulin, which acts as a precursor for insulin. An increase in R&D for novel mechanisms, as well as a rise in the number of awareness programs and collaborations between academic institutes and industries, is expected to boost the market growth. Eli Lilly, Novo Nordisk, and Sanofi are the major vendors in the market. Lantus, NovoRapid, and Humalog are the top-selling products in the market.

Furthermore, our report provides a brief analysis of historical and forecast market share and their segment along with their reasons for growth from 2017 to 2027. The growth of this segment is primarily attributed to the increasing adoption of type 2 diabetes therapeutics, which is driven by an increase in the global prevalence of type 2 diabetes.

Which are the Key Regions for the Type 2 Diabetes Market?

Type 2 Diabetes Market Share by Geography

For more insights on the market share of various regions Request PDF Sample now!

We have covered key regions such as North America, Europe, Asia, and the Rest of the World (ROW) that will experience significant growth during the forecast period. North America is projected to contribute 38% by 2027. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The growth of the type 2 diabetes market in North America is driven by the increasing prevalence of diabetes in North America. For instance, according to the CDC, in 2018, 34.2 million people belonging to all age groups, or 10.5% of the US population, had diabetes. Out of this, 26.9 million people from all age groups or 8.2% of the US population, had diabetes that had been diagnosed. The US, Canada, and Mexico have the highest proportion of people with diabetes in the region. The US is the major contributor to revenue in the market due to the large base diabetic population, sophisticated healthcare infrastructure, and growing technological advances. Canada and Mexico follow the US and are next to major revenue generators in North America. The availability of advanced drugs is likely to spur the demand for the type 2 diabetes therapeutics market in these countries.

The outbreak of COVID-19 in 2020 affected all countries in North America, especially the US. The pandemic also had a slight negative impact on the market in North America in the same year. A rise in the number of COVID-19 cases in the first quarter of 2020 led to partial lockdowns in several countries, including Canada and Mexico. Thus, various non-urgent treatments and clinical visits were either limited or temporarily stopped as per the set guidelines. Some scheduled treatments were either delayed or postponed. Hence, the adoption of type 2 diabetes therapeutics declined slightly, which impacted market growth in 2020 and Q1 2021 to some extent. However, by the second half of 2020, restrictions in various countries were somewhat relaxed, which included the resumption of business activities. The relaxation of the lockdown allowed people to go for health checkups and treatments, which is expected to drive the growth of the type 2 diabetes therapeutics market in North America during the forecast period.

Segment Overview

Our report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by drug class, distribution channel, and region.

  • Drug Class Outlook ( USD Billion, 2017 - 2027)
    • Insulin
    • DPP-4 inhibitor
    • GLP-1 receptor agonists
    • SGLT-2 inhibitors
    • Others
  • Distribution Channel Outlook ( USD Billion, 2017 - 2027)
    • Retail pharmacies
    • Hospital pharmacies
    • Online pharmacies
  • Region Outlook ( USD Billion, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Rest of Europe
    • APAC
      • China
      • India
    • Middle East & Africa
      • Saudi Arabia
      • South Africa
      • Rest of the Middle East & Africa

Type 2 Diabetes Market Scope

Report Coverage

Details

Page number

120

Base year

2022

Historical year

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 10.94%

Market growth 2023-2027

USD 39.37 billion

Market structure

Fragmented

YoY growth (%)

9.49

Regional analysis

North America, Europe, Asia, and the Rest of the World (ROW)

Performing market contribution

North America at 38%

Key consumer countries

US, Germany, UK, China, and India

Competitive landscape

Leading companies, Competitive Strategies, Consumer engagement scope

Key companies profiled

Amgen Inc., AstraZeneca Plc, Baxter International Inc., Biocon Ltd., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Daiichi Sankyo Co. Ltd., DM Pharma Marketing Pvt. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Johnson & Johnson, Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Practo Technologies Pvt. Ltd., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Tonghua Dongbao Pharmaceutical Co. Ltd.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Type 2 Diabetes Market Report?

  • CAGR of the market during the forecast period 2023-2027
  • Detailed information on factors that will drive the growth of the type 2 diabetes market between 2023 and 2027
  • Precise estimation of the Type 2 diabetes market size and its contribution to the parent market.
  • Accurate predictions about  upcoming trends and changes in consumer behavior
  • Growth of the type 2 diabetes industry across North America, Europe, Asia, and the Rest of the World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive details of factors that will challenge the growth of type 2 diabetes market vendors

 

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global type 2 diabetes market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global type 2 diabetes market 2017 - 2021 ($ billion)
    • 4.2 Drug class Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Drug class Segment 2017 - 2021 ($ billion)
    • 4.3 Distribution channel Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Distribution channel Segment 2017 - 2021 ($ billion)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Drug Class

    • 6.1 Market segments
      • Exhibit 30: Chart on Drug Class - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Drug Class - Market share 2022-2027 (%)
    • 6.2 Comparison by Drug Class
      • Exhibit 32: Chart on Comparison by Drug Class
      • Exhibit 33: Data Table on Comparison by Drug Class
    • 6.3 Insulin - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Insulin - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 35: Data Table on Insulin - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 36: Chart on Insulin - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Insulin - Year-over-year growth 2022-2027 (%)
    • 6.4 DPP-4 inhibitor - Market size and forecast 2022-2027
      • Exhibit 38: Chart on DPP-4 inhibitor - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 39: Data Table on DPP-4 inhibitor - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 40: Chart on DPP-4 inhibitor - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on DPP-4 inhibitor - Year-over-year growth 2022-2027 (%)
    • 6.5 GLP-1 receptor agonists - Market size and forecast 2022-2027
      • Exhibit 42: Chart on GLP-1 receptor agonists - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 43: Data Table on GLP-1 receptor agonists - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 44: Chart on GLP-1 receptor agonists - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on GLP-1 receptor agonists - Year-over-year growth 2022-2027 (%)
    • 6.6 SGLT-2 inhibitors - Market size and forecast 2022-2027
      • Exhibit 46: Chart on SGLT-2 inhibitors - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 47: Data Table on SGLT-2 inhibitors - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 48: Chart on SGLT-2 inhibitors - Year-over-year growth 2022-2027 (%)
      • Exhibit 49: Data Table on SGLT-2 inhibitors - Year-over-year growth 2022-2027 (%)
    • 6.7 Others - Market size and forecast 2022-2027
      • Exhibit 50: Chart on Others - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 51: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 52: Chart on Others - Year-over-year growth 2022-2027 (%)
      • Exhibit 53: Data Table on Others - Year-over-year growth 2022-2027 (%)
    • 6.8 Market opportunity by Drug Class
      • Exhibit 54: Market opportunity by Drug Class ($ billion)

    7 Market Segmentation by Distribution Channel

    • 7.1 Market segments
      • Exhibit 55: Chart on Distribution Channel - Market share 2022-2027 (%)
      • Exhibit 56: Data Table on Distribution Channel - Market share 2022-2027 (%)
    • 7.2 Comparison by Distribution Channel
      • Exhibit 57: Chart on Comparison by Distribution Channel
      • Exhibit 58: Data Table on Comparison by Distribution Channel
    • 7.3 Retail pharmacies - Market size and forecast 2022-2027
      • Exhibit 59: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 60: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 61: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
      • Exhibit 62: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
    • 7.4 Hospital pharmacies - Market size and forecast 2022-2027
      • Exhibit 63: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 64: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 65: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
      • Exhibit 66: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
    • 7.5 Online pharmacies - Market size and forecast 2022-2027
      • Exhibit 67: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 68: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 69: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
      • Exhibit 70: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)
    • 7.6 Market opportunity by Distribution Channel
      • Exhibit 71: Market opportunity by Distribution Channel ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 73: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 74: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 75: Chart on Geographic comparison
      • Exhibit 76: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 77: Chart on North America - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 78: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 79: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 81: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 82: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 83: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 85: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 86: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 87: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 89: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 90: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 91: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 93: Chart on US - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 94: Data Table on US - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 95: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 Germany - Market size and forecast 2022-2027
      • Exhibit 97: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 98: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 99: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 100: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.9 China - Market size and forecast 2022-2027
      • Exhibit 101: Chart on China - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 102: Data Table on China - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 103: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 104: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.10 UK - Market size and forecast 2022-2027
      • Exhibit 105: Chart on UK - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 106: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 107: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 108: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.11 India - Market size and forecast 2022-2027
      • Exhibit 109: Chart on India - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 110: Data Table on India - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 111: Chart on India - Year-over-year growth 2022-2027 (%)
      • Exhibit 112: Data Table on India - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 113: Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 114: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 115: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 116: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 117: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 118: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 119: Matrix on vendor position and classification
            • 12.3 Amgen Inc.
              • Exhibit 120: Amgen Inc. - Overview
              • Exhibit 121: Amgen Inc. - Product / Service
              • Exhibit 122: Amgen Inc. - Key offerings
            • 12.4 AstraZeneca Plc
              • Exhibit 123: AstraZeneca Plc - Overview
              • Exhibit 124: AstraZeneca Plc - Product / Service
              • Exhibit 125: AstraZeneca Plc - Key news
              • Exhibit 126: AstraZeneca Plc - Key offerings
            • 12.5 Biocon Ltd.
              • Exhibit 127: Biocon Ltd. - Overview
              • Exhibit 128: Biocon Ltd. - Business segments
              • Exhibit 129: Biocon Ltd. - Key offerings
              • Exhibit 130: Biocon Ltd. - Segment focus
            • 12.6 Boehringer Ingelheim International GmbH
              • Exhibit 131: Boehringer Ingelheim International GmbH - Overview
              • Exhibit 132: Boehringer Ingelheim International GmbH - Business segments
              • Exhibit 133: Boehringer Ingelheim International GmbH - Key news
              • Exhibit 134: Boehringer Ingelheim International GmbH - Key offerings
              • Exhibit 135: Boehringer Ingelheim International GmbH - Segment focus
            • 12.7 Cadila Pharmaceuticals Ltd.
              • Exhibit 136: Cadila Pharmaceuticals Ltd. - Overview
              • Exhibit 137: Cadila Pharmaceuticals Ltd. - Product / Service
              • Exhibit 138: Cadila Pharmaceuticals Ltd. - Key offerings
            • 12.8 Daiichi Sankyo Co. Ltd.
              • Exhibit 139: Daiichi Sankyo Co. Ltd. - Overview
              • Exhibit 140: Daiichi Sankyo Co. Ltd. - Business segments
              • Exhibit 141: Daiichi Sankyo Co. Ltd. - Key news
              • Exhibit 142: Daiichi Sankyo Co. Ltd. - Key offerings
              • Exhibit 143: Daiichi Sankyo Co. Ltd. - Segment focus
            • 12.9 Eli Lilly and Co.
              • Exhibit 144: Eli Lilly and Co. - Overview
              • Exhibit 145: Eli Lilly and Co. - Product / Service
              • Exhibit 146: Eli Lilly and Co. - Key offerings
            • 12.10 Glenmark Pharmaceuticals Ltd.
              • Exhibit 147: Glenmark Pharmaceuticals Ltd. - Overview
              • Exhibit 148: Glenmark Pharmaceuticals Ltd. - Product / Service
              • Exhibit 149: Glenmark Pharmaceuticals Ltd. - Key offerings
            • 12.11 Merck KGaA
              • Exhibit 150: Merck KGaA - Overview
              • Exhibit 151: Merck KGaA - Business segments
              • Exhibit 152: Merck KGaA - Key news
              • Exhibit 153: Merck KGaA - Key offerings
              • Exhibit 154: Merck KGaA - Segment focus
            • 12.12 Novartis AG
              • Exhibit 155: Novartis AG - Overview
              • Exhibit 156: Novartis AG - Business segments
              • Exhibit 157: Novartis AG - Key offerings
              • Exhibit 158: Novartis AG - Segment focus
            • 12.13 Novo Nordisk AS
              • Exhibit 159: Novo Nordisk AS - Overview
              • Exhibit 160: Novo Nordisk AS - Business segments
              • Exhibit 161: Novo Nordisk AS - Key offerings
              • Exhibit 162: Novo Nordisk AS - Segment focus
            • 12.14 Pfizer Inc.
              • Exhibit 163: Pfizer Inc. - Overview
              • Exhibit 164: Pfizer Inc. - Product / Service
              • Exhibit 165: Pfizer Inc. - Key news
              • Exhibit 166: Pfizer Inc. - Key offerings
            • 12.15 Sanofi SA
              • Exhibit 167: Sanofi SA - Overview
              • Exhibit 168: Sanofi SA - Business segments
              • Exhibit 169: Sanofi SA - Key news
              • Exhibit 170: Sanofi SA - Key offerings
              • Exhibit 171: Sanofi SA - Segment focus
            • 12.16 Takeda Pharmaceutical Co. Ltd.
              • Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Overview
              • Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Key news
              • Exhibit 175: Takeda Pharmaceutical Co. Ltd. - Key offerings
            • 12.17 Tonghua Dongbao Pharmaceutical Co. Ltd.
              • Exhibit 176: Tonghua Dongbao Pharmaceutical Co. Ltd. - Overview
              • Exhibit 177: Tonghua Dongbao Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 178: Tonghua Dongbao Pharmaceutical Co. Ltd. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 179: Inclusions checklist
                • Exhibit 180: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 181: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 182: Research methodology
                • Exhibit 183: Validation techniques employed for market sizing
                • Exhibit 184: Information sources
              • 13.5 List of abbreviations
                • Exhibit 185: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              Type 2 Diabetes market growth will increase by $29.91 billion during 2020-2025.
              The type 2 diabetes market is expected to grow at a CAGR of 10.00% during 2020-2025.
              Technavio has segmented the type 2 diabetes market by other1 (Insulin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors, and Others) and geographic (North America, Europe, Asia, and ROW).
              Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Sanofi SA, Takeda Pharmaceutical Co. Ltd. are a few of the key vendors in the type 2 diabetes market.
              North America will register the highest growth rate of 33.83% among the other regions. Therefore, the type 2 diabetes market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              The key factors driving the type 2 diabetes market growth are:
              • Rising prevalence of diabetes
              The type 2 diabetes market vendors should focus on grabbing business opportunities from the insulin segment as it accounted for the largest market share in the base year.
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted
              Technavio

              info
              close
              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Technavio
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>